ArticleAdvanced pharmaceutical bulletin2026
The Effects of Coenzyme Q10 Supplementation on the Contrast Sensitivity Score, Biomarkers of Oxidative Stress, Inflammation, and β-Secretase Activity in the Blood and the Correlation Among these Factors in Diabetic Retinopathy Patients; Clinical Trial.
Article in Advanced pharmaceutical bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic retinopathy (DR), the most common complication of diabetes and is recognized as the leading cause of visual impairment. Coenzyme Q10 (CoQ10) is a nonenzymatic antioxidant that restores other antioxidants, and its benefits in reducing inflammation in various disorders have been demonstrated. In this context, the primary aim of this survey was to evaluate the beneficial effects of CoQ10 on oxidative status, pro-inflammatory cytokines, β-secretase (BACE1) activity, and contrast sensitivity (CS) score in DR patients, and more importantly, the correlation of BACE1 with oxidative status and inflammatory parameters. Methods: 74 DR patients (38 females and 36 males) were divided into two groups as placebo and CoQ10. The treatment process took 12 weeks. One group received 200mg cellulose acetate as a placebo, and the other group received 200 mg CoQ10. Before and after finishing the treatment process, 10ml of venous blood samples were taken from all participants to measure changes in CoQ10, Total Antioxidant Capacity (TAC), Total Oxidant Status (TOS), Glutathione (GSH), Malondialdehyde (MDA), Catalase activity (CAT), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), and BACE1 activity in the serum. Moreover, the CS scores were also evaluated. Results: all the measured oxidative stress and inflammatory parameters, BACE1 activity, and also CS score were attenuated after treatment with CoQ10 in the DR patients ( Conclusion: CoQ10 supplementation increases CS score in DR patients, which can be due to a decrease in BACE1 activity. Furthermore, the reduction in BACE1 activity in DR patients was partly related to the enhancement of the antioxidant defense system and a reduction in inflammation, as there was a high correlation between BACE1 activity and these parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.